SV2002000473A - Ziprasidona-dihidro-metil-s para el tratamiento de los desordenes psiquiatricos y oculares ref.pcll029/20208/bb - Google Patents

Ziprasidona-dihidro-metil-s para el tratamiento de los desordenes psiquiatricos y oculares ref.pcll029/20208/bb

Info

Publication number
SV2002000473A
SV2002000473A SV2001000473A SV2001000473A SV2002000473A SV 2002000473 A SV2002000473 A SV 2002000473A SV 2001000473 A SV2001000473 A SV 2001000473A SV 2001000473 A SV2001000473 A SV 2001000473A SV 2002000473 A SV2002000473 A SV 2002000473A
Authority
SV
El Salvador
Prior art keywords
disorders
treatment
anxiety
psychiatric
demencies
Prior art date
Application number
SV2001000473A
Other languages
English (en)
Inventor
Prakash Chandra Aggarwal
Teresa Annette Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2002000473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000473A publication Critical patent/SV2002000473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN S-METIL-DIHIDRO-ZIPRASIONAS Y AL USO DE DICHO COMPUESTO Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA EL TRATAMIENTO DE TRASTORNOS PSIQUIATRICOS Y OCULARES. . DE UNA MANERA MAS ESPECIFICA, SE REFIERE AL USO DE DICHO COMPUESTO Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA EL TRATAMIENTO DE UN TRASTORNO O AFECCION SELECCIONADO DE ESQUIZOFRENIA, TRASTORNOS DE ANSIEDAD GENERALIZADA, TRASTORNOS DE PANICO, TRASTORNOS DE ESTRES POST-TRAUMATICO Y FOBIAS (POR EJEMPLO, FOBIA SOCIAL, AGORAFOBIA, ETC); EPISODIOS PSICOTICOS DE ANSIEDAD; ANSIEDAD, AGITACION, AGRESIVIDAD EXCESIVA, TENSION O RETRAIMIENTO SOCIAL O EMOCIONAL ASOCIADO CON TRASTORNOS PISCOTICOS COMO LA MANIA AGUDA Y LA DEPRESION ASOCIADAS CON TRASTORNOS BIPOLARES, Y TRASTORNOS DEL ESTADO DE ANIMO ASOCIADOS CON ESQUIZOFRENIA; DESVIACIONES DEL COMPORTAMIENTO ASOCIADAS CON RETRASO MENTAL, TRASTORNOS DE AUTISMO Y TRASTORNOS DE LA CONDUCTA; DEMENCIAS COMO LAS DEMENCIAS ASOCIADAS CON LA ENFERMEDAD DE ALZHEIMER DISNESIAS INDUCIDAS POR DROGAS Y DE BASE NEURODEGENERATIVA; TRASTORNO OBESIVO COMPULSIVO; SINDROME DE TOURETTE; GLAUCOMA; Y RETINOPATIA ISQUEMIA.
SV2001000473A 2000-06-02 2001-06-01 Ziprasidona-dihidro-metil-s para el tratamiento de los desordenes psiquiatricos y oculares ref.pcll029/20208/bb SV2002000473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
SV2002000473A true SV2002000473A (es) 2002-10-24

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000473A SV2002000473A (es) 2000-06-02 2001-06-01 Ziprasidona-dihidro-metil-s para el tratamiento de los desordenes psiquiatricos y oculares ref.pcll029/20208/bb

Country Status (44)

Country Link
US (1) US20060287336A1 (es)
EP (3) EP1286672B1 (es)
JP (2) JP2003534381A (es)
KR (1) KR20030007824A (es)
CN (1) CN1431901A (es)
AP (2) AP1831A (es)
AR (1) AR028937A1 (es)
AT (3) ATE345818T1 (es)
AU (1) AU2001258690A1 (es)
BG (1) BG107267A (es)
BR (1) BR0111271A (es)
CA (1) CA2410618A1 (es)
CY (1) CY1105992T1 (es)
CZ (1) CZ20023860A3 (es)
DE (3) DE60133596D1 (es)
DK (1) DK1468686T3 (es)
DO (1) DOP2001000181A (es)
EA (1) EA007068B1 (es)
EC (1) ECSP024369A (es)
EE (1) EE200200670A (es)
ES (1) ES2277170T3 (es)
GE (1) GEP20053512B (es)
HN (1) HN2001000119A (es)
HR (1) HRP20020953A2 (es)
HU (1) HUP0301747A2 (es)
IL (2) IL152782A0 (es)
IS (1) IS6619A (es)
MA (1) MA26908A1 (es)
MX (1) MXPA02011862A (es)
NO (1) NO325077B1 (es)
NZ (1) NZ551012A (es)
OA (1) OA12267A (es)
PA (1) PA8518301A1 (es)
PE (1) PE20011329A1 (es)
PL (1) PL365576A1 (es)
PT (2) PT1468686E (es)
SI (1) SI1468686T1 (es)
SK (1) SK16622002A3 (es)
SV (1) SV2002000473A (es)
UA (1) UA79425C2 (es)
UY (1) UY26742A1 (es)
WO (1) WO2001091756A2 (es)
YU (1) YU90702A (es)
ZA (1) ZA200209665B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419493B2 (en) 2002-12-13 2008-09-02 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042190A1 (en) * 1996-05-07 1997-11-13 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
EP1165083A2 (en) * 1999-04-06 2002-01-02 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
EP1468686B1 (en) 2006-11-22
ATE345818T1 (de) 2006-12-15
EA200201168A1 (ru) 2003-06-26
UA79425C2 (en) 2007-06-25
AP1747A (en) 2007-05-31
CY1105992T1 (el) 2011-04-06
EP1698338B1 (en) 2008-04-09
PT1698338E (pt) 2008-06-03
EE200200670A (et) 2004-08-16
SI1468686T1 (sl) 2007-04-30
MXPA02011862A (es) 2003-04-10
US20060287336A1 (en) 2006-12-21
DK1468686T3 (da) 2007-03-12
OA12267A (en) 2004-01-20
EP1698338A2 (en) 2006-09-06
AP2005003272A0 (en) 2005-03-31
WO2001091756A3 (en) 2002-09-26
ES2277170T3 (es) 2007-07-01
JP2008056700A (ja) 2008-03-13
SK16622002A3 (sk) 2004-07-07
EP1286672A2 (en) 2003-03-05
ATE391507T1 (de) 2008-04-15
PT1468686E (pt) 2007-01-31
DE60124093D1 (de) 2006-12-07
UY26742A1 (es) 2001-12-28
NO20025760L (no) 2003-01-15
NO20025760D0 (no) 2002-11-29
EP1698338A3 (en) 2006-09-20
MA26908A1 (fr) 2004-12-20
CA2410618A1 (en) 2001-12-06
AP1831A (en) 2008-02-26
PE20011329A1 (es) 2002-01-15
NZ551012A (en) 2008-04-30
ATE343387T1 (de) 2006-11-15
AR028937A1 (es) 2003-05-28
ZA200209665B (en) 2003-11-28
WO2001091756A2 (en) 2001-12-06
HN2001000119A (es) 2001-09-11
DE60133596D1 (de) 2008-05-21
PL365576A1 (en) 2005-01-10
BR0111271A (pt) 2003-06-10
KR20030007824A (ko) 2003-01-23
HRP20020953A2 (en) 2005-02-28
EP1468686A2 (en) 2004-10-20
YU90702A (sh) 2005-11-28
EP1286672B1 (en) 2006-10-25
JP2003534381A (ja) 2003-11-18
DE60124791D1 (de) 2007-01-04
DE60124791T2 (de) 2007-09-13
IL152782A0 (en) 2003-06-24
IS6619A (is) 2002-11-14
ECSP024369A (es) 2003-02-06
EP1468686A3 (en) 2004-12-01
AU2001258690A1 (en) 2001-12-11
PA8518301A1 (es) 2002-09-17
EA007068B1 (ru) 2006-06-30
NO325077B1 (no) 2008-01-28
IL152782A (en) 2007-10-31
DOP2001000181A (es) 2002-04-15
GEP20053512B (en) 2005-05-10
BG107267A (bg) 2003-06-30
HUP0301747A2 (hu) 2003-09-29
CN1431901A (zh) 2003-07-23
CZ20023860A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
CO6321153A2 (es) Derivados de cromeno y cromano y sus usos
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CR11095A (es) Compuestos amino-heterociclicos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
GT200500375A (es) Derivados de piperidina y su uso como agentes antiinflamatorios
CR7042A (es) Indanil aminas aciladas y su uso como farmacos
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
CO6321264A2 (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
GT200100183A (es) Derivados de quinolina y quinazolina.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
UY29673A1 (es) Derivados sustituidos de 6-(4-clorofenil) tieno (3,2,d)- pirimidin- 4(3h)-ona y (1,2,3,)-triazin-4-(3h)-ona,composiciones farmaceuticas conteniéndolos, procesosde peparación y aplicaciones.
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
GT200200039A (es) Uso de agonistas inversos de gaba a en combinacion con agonistas parciales del receptor de nicotina, estrogenos,moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos
UY28400A1 (es) Metabolito
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ES2067874T3 (es) Derivados de acetamida.
SV2002000473A (es) Ziprasidona-dihidro-metil-s para el tratamiento de los desordenes psiquiatricos y oculares ref.pcll029/20208/bb
ES2152016T3 (es) Solucion oftalmica de pranoprofeno conteniendo amina organica.
GT200500348A (es) Pirazolo[3,4-b]piridinas e indazoles terpeuticos
BR112023022514A2 (pt) Oligonucleotídeos antissenso e seu uso para tratamento de distúrbios neurodegenerativos

Legal Events

Date Code Title Description
FD Lapse